About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Biotest image

Biotest

Rank#5012
Market Cap1.63B
CountryGermany
Summary
History
Mission
Vision
References
Summaryarrow
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
Historyarrow

Biotest was founded in 1945 in Dreieich and is a leading provider of plasma products and biotherapeutics. It is the main supplier of the entire range of human coagulation factors to treat congenital and acquired bleeding disorders and haemophilia.

Missionarrow
At Biotest, we have the ultimate mission to save lives and improve the quality of life for critically and chronically ill people.
Visionarrow
We are driven by a simple yet profound vision: to be the world's premier biotechnology company.
Referencesarrow

https://de.wikipedia.org/wiki/Biotest

https://in.investing.com/equities/biotest

https://finance.yahoo.com/quote/BIO.DE/profile?p=BIO.DE

https://www.crunchbase.com/organization/biotest-ag-2

https://companiesmarketcap.com/

https://www.biotest.com

Share

Leadership team
D
Dr. Michael Ramroth (Chairman of the Management Board, CEO & CFO)
D
Dr. Georg Floß (COO & Member of the Board of Management)
D
Dr. Jorg Schuttrumpf (Chief Scientific Officer & Member of the Management Board)
Products / Services
Biotechnology, Health Care
Number of Employees
1,000 - 20,000
Address
Dreieich, Hessen, Germany
Established
1946-01-01
Revenue
500M - 1B
Traded as
BIO.F
Website
https://www.biotest.com
Social Media
linkedinfacebookx
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo